Analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report released on Tuesday. The brokerage set a “hold” rating on the biotechnology company’s stock. Several other research analysts also recently commented on the stock. Brookline Capital Management downgraded shares of Cyclacel Pharmaceuticals from a “buy” rating to […] Read this story